Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 40Ovarian Neoplasms 32Triple Negative Breast Neoplasms 20Prostatic Neoplasms 17Fallopian Tube Neoplasms 16Neoplasm Metastasis 14Endometrial Neoplasms 10Pancreatic Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Glioma 6Stomach Neoplasms 5Sarcoma 5Lung Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Metastatic Castration-resistant Prostate Cancer 4Carcinoma, Ovarian Epithelial 4Solid Tumors 3Recurrence 3Osteosarcoma 3Lymphoma, Non-Hodgkin 3Cholangiocarcinoma 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms, Castration-Resistant 2

Interventions

Cyclophosphamide 34Doxorubicin 24fludarabine phosphate 20Vinblastine 20Nivolumab 20Dacarbazine 20Brentuximab Vedotin 20pembrolizumab 19fludarabine 18Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Filgrastim 13Melphalan 12Granulocyte Colony-Stimulating Factor 10Gemcitabine 10Bleomycin 10Tacrolimus 9Radiotherapy 9Prednisone 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Specimen Handling 8Vincristine 7Sirolimus 7Magnetic Resonance Spectroscopy 7Cyclosporine 7pegfilgrastim 6Stem Cell Transplantation 6Bendamustine Hydrochloride 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × olaparib × 1 year × Clear all
NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1 Completed
50 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡